肿瘤细胞治疗研究
ALL SOURCES
TFRC-mediated immune exclusion as a therapeutic vulnerability in cervical cancer: A comprehensive analysis based on the cancer immunoediting process.
我们的研究为 CC 患者提供了一种基于 CIC 的新型分层工具，并确定 TFRC 是免疫排斥的关键调节因子。这些发现表明，靶向 TFRC 不仅能抑制内在的肿瘤进展，还可能通过重塑免疫微环境使 CC 对免疫治疗敏感。
Prognostic impact of HLA-G expression in cervical squamous cell carcinoma: correlation with PD-L1 and CD8-positive tumor infiltrating lymphocytes.
本研究证实，HLA-G/sHLA-G表达升高是宫颈癌的独立不良预后因素。
Circulating and tumor-infiltrating immune cell profiles in cervical cancer checkpoint blockade: multi-omics biomarkers of response and resistance.
Beyond approval: a mechanism-based review of novel anti-tumour agents in cervical cancer and when to use them.
Tumor immune microenvironment in cervical cancer: Histological subtype-specific immune landscapes and therapeutic implications.
Development and preclinical evaluation of KDTV001, an adenovirus 5-vectored trivalent HPV therapeutic vaccine targeting HPV16/18/52.
GBP6 maintains mitochondrial bioenergetics to promote immune evasion from NK cells in cervical cancer.
A low-dose self-amplifying mRNA vaccine encoding HPV16 E6/E7 induces potent T-cell immunity and antitumor protection in mice.
JJ-saRNA-HPV01 在低剂量（0.1-1 μg）下通过促进 T 细胞浸润、增强 IFN-γ分泌和下调 PD-1 表达，诱导强效抗肿瘤免疫。其预防/治疗双重功效、剂量节省优势及长期保护作用支持在 HPV 相关癌症中进行临床转化，尤其是在资源有限的环境中。未来研究应聚焦于提高 E6 免疫原性及与免疫检查点抑制剂联合应用的评估。
Oligoclonal tumor-specific CD8 T-cell revival and IRE1α/XBP1-GDF15-mediated immunosuppressive niches determine neoadjuvant chemoimmunotherapy efficacy
本研究提供了关键见解，表明 NACI 耐药源于 DTP 细胞中的适应性 ER 应激信号以及空间组织的免疫抑制网络。靶向 IRE1/XBP1-GDF15 轴是一种可操作的策略，可重编程微环境生态并改善免疫治疗结局。
MEMBER ACCOUNT
登录成功会直接打开下一页。
